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Abstract
This review focuses on the most recent scientiﬁc and clinical information on the development and clinical applicability of
the cell cycle biomarkers TIMP-2 and IGFBP-7 in the diagnosis and prognosis of patients at risk for and suffering from acute
kidney injury (AKI). A number of evaluation studies have demonstrated that compared with existing biomarkers, urinary
excretion of the product of both biomarkers, [TIMP-2]•[IGFBP-7], improved diagnostic performance in assessing the risk for AKI,
predicting the need for renal replacement therapy, AKI-related complications and short- and long-term prognoses. The
reference intervals for these biomarkers, measured by the recently approved NephroCheck test, have been determined in
apparently healthy adults and those with stable chronic morbid conditions without AKI. This review recognizes that the
combination of these two cell cycle arrest markers for the early detection of AKI is promising but concludes that its clinical
impact is still unproved. Clinicians should understand the utility and limitations of this test before decidingwhether tomake it
available at their institution.
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Introduction
During the past decade, the use of consensus deﬁnitions of acute
kidney injury (AKI), including RIFLE (Risk, Injury, Failure, Loss,
ESRD), AKIN (Acute Kidney Injury Network) and KDIGO (Kidney
Disease: Improving Global Outcomes), has uniﬁed most of the
recent epidemiological studies on AKI [1–3].
The KDIGO criteria stage patients according to changes in
serum creatinine (SCr) and urine output rather than changes in
glomerular ﬁltration rate (GFR). Both SCr and urine output criteria
are important predictors, and the use of the KDIGO deﬁnition
without assessment of urine output underestimates the inci-
dence and grade of AKI and can delay diagnosis [4–7]. In addition,
an association between episodes of oliguria and greater risks of
worsening AKI, need for renal replacement therapy (RRT) and
death has been established [5, 7–10].
However, numerous studies have omitted the urine output
contribution in the deﬁnition of AKI [11]. It should further be rea-
lized that SCr often lags behind the actual occurrence of renal
functional alterations or structural tubular or other intrarenal
cellular injuries [12, 13].
Furthermore, SCr is also limited because its concentration is
affected by factors such as muscle mass, intravascular volume,
assay interference and drug interactions [14, 15]. Thus, changes
in SCr levels do not accurately or consistently reﬂect real-time
changes in renal function. Similarly, damage to the renal tubular
epithelia may not be reﬂected in SCr levels or urine output until
the damage progresses to a critical threshold.
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Extensive effort has been expended over the past 15 years to
identify and validate novel biomarkers that are more sensitive
to the onset of injury, speciﬁc for prediction and have greater dis-
crimination for injury severity.
Essentially, three types of novel biomarkers have been identi-
ﬁed in the ﬁeld of AKI. The ﬁrst group is inﬂammatory biomar-
kers, including neutrophil gelatinase-associated lipocalin
(NGAL) and pro-inﬂammatory cytokines such as interleukin-6
(IL-6) and IL-18. The second group includes cell injury biomarkers
such as kidney injury molecule-1 (KIM-1), liver fatty acid-binding
protein (L-FABP), sodium/hydrogen exchanger 3 (NHE-3) and ne-
trin 1. The third recently identiﬁed group consists of cell cycle
markers, such as urinary tissue inhibitor of metalloproteinase 2
(TIMP-2) and insulin-like growth factor-binding protein 7
(IGFBP-7). Ideally, these markers could facilitate, earlier and/or
more accurately than is possible with SCr and urine output,
the diagnosis and differential diagnosis of AKI [12, 16, 17] and
could predict the need for RRT, AKI-related complications and
short- and long-term prognoses [18]. Many recent in-depth
reviews have summarized the characteristics, advantages and
limitations of the ﬁrst two groups of biomarkers [18–20].
This review focuses on themore recently developed cell cycle
markers.
Biological role of the cell cycle biomarkers
Each phase of the cell cycle has a speciﬁc function that is required
for appropriate cell proliferation. Quiescent cells are normally in
G0. For cells to divide and begin the process of repair, they must
enter and exit each phase of the cell cycle on schedule [21–23].
Cyclins, cyclin-dependent kinases and cyclin-dependent kinase
inhibitors control each phase of the cell cycle [22]. If the cell
exits a phase too soon or stays in a phase too long, the normal re-
pair and recovery process can becomemaladaptive [22]. Exit from
the cell cycle in late G1 leads to apoptosis [24]. Failure to achieve
G1 cell cycle arrest can lead to an increased proportion of renal
tubular cells in the G2/M phase, producing proﬁbrotic growth fac-
tors that are capable of stimulating ﬁbroblast proliferation and
collagen production. In the animal model, this process is corre-
lated with lasting kidney damage, including extensive glomeru-
losclerosis and interstitial ﬁbrosis [23].
On the other hand, G1 cell cycle arrest may prevent the
division of cells with damaged DNA until the DNA damage is re-
paired [25]. Thus the cell uses cell cycle arrest as a protective
mechanism whereby cell division is avoided during stress and
injury. However, if the cells do not reinitiate the cell cycle and
remain arrested at G1 or G2 (or possibly other phases of the
cell cycle), this sustained cell cycle arrest will result in a senes-
cent cell phenotype and lead to ﬁbrosis [26], and a hypertrophic
and ﬁbrotic phenotype can ensue (for recent excellent reviews
see [26, 27]).
The cell cycle biomarkers have been shown to be involved in a
diverse array of biologic processes, including cell cycle arrest.
In the setting of cell cycle arrest, these proteins signal activa-
tion of the p-protein cascade (p53, p21 and p27), which in turn
blocks the effect of the cyclin-dependent protein kinase com-
plexes [28–32].
The complexities of these pathways have been studied in the
setting of AKI/cisplatin cytotoxicity, where p21 is known to in-
hibit cyclin-dependent protein kinase-2 and phosphorylation of
p21 alters the cellular response to this toxin [33–35].
Additionally, TIMP-2 has been shown to be an important com-
ponent in the pathophysiology of ischaemia-reperfusion injury,
where various subtypes of TIMP proteins may play different
roles in the kidney. Wang et al. [36] have shown that each TIMP
subtype has a distinct role in renal injury. While TIMP-3 is re-
quired for optimal response to renal injury, TIMP-2 appears to
promote disease progression through the activation of matrix
metalloproteinase and triggering of tubulointerstitial ﬁbrosis
and injury. Similarly, research studies in renal transplant allo-
grafts show that matrix metalloproteinase activity is important
in mediating scarring in chronic allograft nephropathy [37].
IGFBP-7 is a secreted protein that is a member of the IGFBP
superfamily, also known as IGFBP-related proteins. IGFs exhibit
pleiotropic effects in development and disease, and IGFBP-7
regulates the bioavailability of IGFs through direct low-afﬁnity
binding [38]. Several IGF-independent effects, such as tumor sup-
pression in melanoma and colon cancer and induction of cell
senescence in breast cancer lines, are also ascribed to IGFBP-7
[31, 32].
AKI has increasingly been recognized as a major contributor
to chronic and end-stage kidney disease, and the appearance of
tubulointerstitial ﬁbrosis during the repair phase after either is-
chaemic or toxic injury is a poor prognostic indicator and repre-
sents a common ﬁnal pathway in the progression to end-stage
renal disease. By detecting cell cycle arrest markers in the
urine, one may actually be detecting cell stress. This stress may
or may not lead to damage and functional decline, but it is the
earliest possible point in the process that can be detected [39].
Upregulation of TIMP-2 and IGFBP-7 in patients with AKI has
been proposed to reﬂect their growth inhibitory functions [40].
Although there are suggestive arguments for a direct role of
both TIMP-2 and IGFBP-7 in the cell cycle arrest mechanisms
and IGFBP-7 and TIMP-2 are expressed in the tubular cells as a re-
sponse to DNA and possibly other forms of damage, their exact
biological role in AKI beyond their utility as biomarkers is still
not fully understood since both proteins are capable of inducing
a wide variety of cellular responses. As stressed by Vijayan et al.
[41], there is much that remains poorly understood regarding the
biological role for these proteins in AKI beyond their utility as bio-
markers. Their presumed role as inducers of G1 cell cycle arrest in
the kidney remains speculative, given that these proteins are
capable of inducing a wide variety of cellular responses.
Clinical studies with cell cycle biomarkers
The ﬁrst major study on the role of the cell cycle markers in AKI
was the international Sapphire study, in which the ability of 340
proteins, including known AKI biomarkers, to predict develop-
ment of AKI was tested in a heterogeneous group of critically ill
intensive care unit (ICU) patients [42]. The identiﬁed proteins re-
presented multiple biological pathways believed to be important
in the pathogenesis of AKI. The report of this study included two
multicentre studies, a discovery phase and a validation phase. In
the discovery phase, 522 adults were enrolled in three distinct co-
horts including patients with sepsis, shock, major surgery and
trauma. In the validation phase, the ﬁnal analysis cohort con-
tained 728 critically ill patients. The primary endpoint was mod-
erate–severe AKI (KDIGO stage 2–3) [1] within 12 h of sample
collection. In the Sapphire study, the product of the two urinary
biomarkers, [TIMP-2]•[IGFBP-7], provided an areaunder the curve
(AUC) of 0.80 [95% conﬁdence interval (CI) 0.74–0.84] for severe
AKI (n = 101; 14% of the total) in the validation cohort, with indi-
vidual biomarkers providing an AUC of 0.79 and 0.76, respective-
ly. [TIMP-2]•[IGFBP-7] was signiﬁcantly superior to all previously
described markers of AKI (P < 0.002), including NGAL and KIM-1,
none of which achieved an AUC >0.72 [42], when also assessed
in a heterogeneous population.
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A primary clinical cut-off value (0.3 ng/mL2/1000) for the com-
bination of the two biomarkers was derived from the Sapphire
study data and veriﬁed in a new cohort of 153 critically ill patients
(Opal study) [43]. This cut-off was selected to have high sensitiv-
ity for the primary endpoint of moderate–severe AKI in the next
12 h, with the intent of use in routine clinical practice to identify
patients at high risk for AKI. It is hoped that these patients
could be candidates for so-called kidney-sparing management
strategies such as those outlined in the KDIGO guideline for
high-risk patients [1]. A second, high-speciﬁcity cut-off (2.0 ng/
mL2/1000) was selected and veriﬁed to identify the subgroup of
patients who are at the highest risk of AKI and who therefore
might be appropriate for more active interventions. The Opal
study implemented cut-off values for [TIMP-2]•[IGFBP-7], with a
high-sensitivity cut-off of 0.3 ng/mL2/1000 providing a sensitivity
of 95% (95% CI 85–98%) and a speciﬁcity of 46% (95% CI 41–52%),
whereas a high-speciﬁcity cut-off of 2.0 ng/mL2/1000 provided a
sensitivity of 37% (95% CI 26–47%) and a speciﬁcity of 95% (95%
CI 93–97%).
Both cut-offs (0.3 and 2.0)were subsequently validated in a 23-
site study of 408 critically ill patients in the USA (Topaz study)
using clinical adjudication to determine the primary endpoint
of moderate–severe AKI. The high-sensitivity cut-off value of
0.3 ng/mL2/1000 was tested against a clinical model containing
several clinical covariates, while three clinical nephrologists
who were blinded to the biomarker ﬁndings were asked to deter-
mine whether moderate to severe AKI was reached for each pa-
tient [44]. Critically ill patients with urinary [TIMP-2]•[IGFBP-7]
levels >0.3 ng/mL2/1000 had 7 times the risk for AKI (95% CI 4–
22) compared with critically ill patients with a test result <0.3.
In multivariate analysis, urinary [TIMP-2]•[IGFBP-7] remained a
statistically signiﬁcant and strong predictor of AKI when com-
bined with the clinical model. The AUC of the combined urinary
[TIMP-2]•[IGFBP-7] test and clinical model of 0.86 (95% CI 0.80–
0.90) was signiﬁcantly (P < 0.001) improved compared with the
clinical model alone [AUC 0.70 (95% CI 0.63–0.76)]. It is striking,
however, that great overlap exists in the lower-range values.
Only in values >2.0 is no major overlap present.
The association of urinary TIMP-2 and IGFBP-7 with long-
term outcomes was recently explored by evaluation of the 9-
month incidence of a composite endpoint of all-cause mortality
or the need for RRT in a secondary analysis of the Sapphire study
in critically ill adults [45]. Again, the same two predeﬁned [TIMP-
2]•[IGFBP-7] cut-offs (0.3 for high sensitivity and 2.0 for high spe-
ciﬁcity) for the development of AKI were evaluated. Cox propor-
tional hazards models were used to determine risk for the
composite endpoint. Baseline [TIMP-2]•[IGFBP-7] values were
available for 692 subjects, of whom 382 (55.2%) developed stage
1 AKI as deﬁned by the KDIGO guidelines [1] within 72 h of en-
rolment and 217 (31.4%) met the composite endpoint. Univariate
analysis showed that a [TIMP-2]•[IGFBP-7] value of 2.0 was asso-
ciated with increased risk of the composite endpoint [hazard
ratio (HR) 2.11 (95% CI 1.37–3.23), P < 0.001]. In amultivariate ana-
lysis adjusted for clinical variables, [TIMP-2]•[IGFBP-7] levels >0.3
were associated with death or RRT only in subjects who devel-
oped AKI. It was concluded that [TIMP-2]•[IGFBP-7] measured
early in the setting of critical illness may identify patients with
AKI at increased risk for mortality or receipt of RRT over the
next 9 months.
Althoughmoderate to severe AKI on ICU admission wasmen-
tioned as an exclusion criterion in the Sapphire study [42], 32 of
101 (31.7%) had already developed KDIGO stage 2 or 3 at the
time of urine sampling.Moreover, baseline creatininewas signiﬁ-
cantly higher in patients who would develop AKI within 12 h.
In addition, a study of 50 patients at high risk of AKI following
cardiac surgery found that maximum urinary [TIMP-2]•[IGFBP-7]
concentrations in the 24 h postoperatively were a sensitive and
speciﬁc predictor of AKI [46]. Of the 50 patients included in the
study, 26 (52%) developed AKI. Diagnosis based on SCr and/or oli-
guria did not occur until 1–3 days after cardiopulmonary bypass
(CPB). In contrast, the urine concentration of [TIMP-2]•[IGFBP-7]
rose from a mean of 0.49 (SE 0.24) at baseline to 1.51 (SE 0.57) 4
h after CPB in patients who developed AKI. The maximum urin-
ary [TIMP-2]•[IGFBP-7] concentration achieved in the ﬁrst 24 h
following surgery (composite time point) demonstrated an AUC
of 0.84. Sensitivity was 0.92 and speciﬁcity was 0.81 for a cut-off
value of 0.50. The decline in urinary [TIMP-2]•[IGFBP-7] values
was the strongest predictor for renal recovery. This small study
suggests that urinary [TIMP-2]•[IGFBP-7] may serve as a sensitive
and speciﬁc biomarker to predict AKI early after cardiac surgery
and to predict renal recovery.
Gocze et al. [47] prospectively measured urinary [TIMP-2]•
[IGFBP-7] excretion in 107 high-risk non-cardiac surgical patients.
Forty-ﬁve of them (42%) developed AKI. A predeﬁned cut-off
value of [TIMP-2]•[IGFBP-7] >0.3 was used for assessing diagnos-
tic accuracy. The highest median values of biomarker were
detected in septic, post-transplant and post-hepatic surgery pa-
tients (1.24 versus 0.45 versus 0.47 ng/mL2/1000). The AUC for
the risk of any AKI was 0.85, for early use of RRT 0.83 and for
28-day mortality 0.77. In a multivariable model with established
perioperative risk factors, the [TIMP-2]•[IGFBP-7] test was the
strongest predictor of AKI and signiﬁcantly improved the risk
assessment.
Another recent study used the cell cycle arrest biomarkers to
predict the development ofmoderate–severeAKI in a large cohort
of heterogeneous, critically ill, postoperative surgical patients
[48]. As was found in the Topaz and Opal studies, when the pre-
speciﬁed cut-off [TIMP-2]•[IGFBP-7] value of 0.3 was used, the
sensitivity of the test was 89% (95% CI 77–97), with an accom-
panying speciﬁcity of 49% (95% CI 43–54), a positive likelihood
ratio of 1.72 (95% CI 1.44–2.01) and a negative likelihood ratio of
0.24 (95% CI 0.06–0.49). Patients with urinary [TIMP-2]•[IGFBP-7]
test values >0.3 had >6 times the risk for AKI compared with
those with a test value at or below the 0.3 cut-off. However, a ra-
ther large overlap in biomarker values between AKI and non-AKI
patients was found.
Finally, the prognostic value of urinary TIMP-2 and IGFBP-7 in
neonatal and paediatric AKI for adverse outcomewas recently in-
vestigated [49]. The urinary concentration of [TIMP-2]•[IGFBP-7]
was assessed by the NephroCheck immunoassay (see below) in
a prospective cohort of 133 subjects ages 0–18 years, including 46
patients with established AKI according to the pRIFLE criteria, 27
patients without AKI (non-AKI Group I) and 60 apparently healthy
neonates and children (non-AKI Group II). After classiﬁcation into
the pRIFLE criteria, 6/46 (13%) patients fulﬁlled the criteria for the
category ‘Risk’, 13/46 (28%) for ‘Injury’, 26/46 (57%) for ‘Failure’ and
1/46 (2%) for ‘Loss’. Patients in the ‘Failure’ stage had amedian 3.7-
fold higher urinary [TIMP-2]•[IGFBP-7] compared with non-AKI
subjects (P < 0.001). Receiver operating characteristic curve ana-
lyses in the AKI group revealed good performance of [TIMP-2]•
[IGFBP-7] in predicting 30-day [AUC 0.79 (95% CI 0.61–0.97)] and
3-monthmortality [AUC0.84 (95%CI 0.67–0.99)] andmoderate per-
formance in predicting RRT [AUC 0.67 (95% CI 0.50–0.84)].
In 2014, the US Food and Drug Administration (FDA) approved
a point-of-care urinary biomarker assay, NephroCheck (Astute
Medical, San Diego, CA, USA), for predicting risk of AKI. This in
vitro test quantitatively measures [TIMP-2]•[IGFBP-7] in human
urine on the ASTUTE140®Meter, a bench/table-top analyzer.
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Recently, the reference intervals for these biomarkers, mea-
sured by the NephroCheck test, were determined in apparently
healthy adults and those with stable chronic morbid conditions
without AKI [50]. The reference intervals (inner 95%) for [TIMP-
2]•[IGFBP-7] in all subjects (n = 750), apparently healthy subjects
(n = 378) and subjects with stable chronic morbidities (n = 372)
were 0.04–2.22, 0.04–2.25 and 0.05–2.20 ng/mL2/1000, respectively.
There was no statistical difference between reference intervals
for the apparently healthy and stable chronic morbid cohorts
(P = 0.42). It is important to mention that in the subjects with
stable chronic comorbidities, patients with stable chronic kidney
disease (CKD) were included. Unfortunately, the degree of CKD
and the absolute number of CKD subjects are not detailed. The
authors conclude that urine [TIMP-2]•[IGFBP-7] values are not
elevated in patients with stable chronic morbidities who did
not have AKI. However, as recognized by the authors, the refer-
ence intervals in apparently healthy and stable chronic morbid
subjects overlap with the values obtained from AKI patients
[50]. Reference interval data show that overall 50% of the popula-
tionhas values >0.33 and the rest of the [TIMP-2]•[IGFBP-7] values
are ≤0.3. As such, the [TIMP-2]•[IGFBP-7] values obtained in crit-
ically ill patients should only be used in conjunction with patient
condition and clinical signs and symptoms. The authors stress
that this test was developed to assess the risk of AKI and was
not intended as a sole indicator for the diagnosis of AKI. Further-
more, in the stable chronic disease patients, a number of patients
suffering from active cancer were included; also, the test popula-
tion in the Sapphire and Topaz studies included 25 and 27% can-
cer patients, respectively. As already outlined above, TIMP-2 can,
in some instances, promote cellular proliferation [30] and is
strongly expressed in renal cell carcinoma, indicating that renal
epithelia are capable of expressing it [51]. It could be of interest
to analyse separately the results of the cell cycle markers in can-
cer patients with and without AKI.
Finally, a recent study fromBell et al. [52] found that in general
ICU patients, the NephroCheck point-of-care analyzer readings
of [TIMP-2]•[IGFBP-7] or measurement of the previously sug-
gested urinary biomarkers NGAL and cystatin C did not predict
AKI within 12–48 h. Biomarker values were signiﬁcantly affected
by comorbidities even in the absence of AKI. These ﬁndings chal-
lenge the robustness and utility of cell cycle arrest biomarkers for
the prediction of AKI in general ICUpatients and also suggest that
their performance may decrease markedly in general ICU pa-
tients with heterogeneous diagnoses, differing comorbidities
and multiple sources of inﬂammation [52].
Recommendations of the American Society of
Nephrology AKI Advisory Group
Very recently, members of the American Society of Nephrology
the AKI Advisory Group, some of whom participated in the clin-
ical studies with cell cycle biomarkers, published interesting and
carefully worded recommendations on the use of these
biomarkers in clinical practice [41]. The advisory group empha-
sizes that the NephroCheck test should only be used in ICU
patients >21 years of age with cardiovascular and/or respiratory
compromise within the prior 24 h. The test is ‘an aid in the risk
assessment for moderate or severe AKI’. The group also re-
minded that the FDA letter states that ‘test results are intended
to be used in conjunction with other clinical and diagnostic ﬁnd-
ings, consistent with professional standards of practice, includ-
ing conﬁrmation by alternative methods’. The FDA decision
summary clariﬁes that [TIMP-2]•[IGFBP-7] is not a standalone
test and should not be used as point-of-care testing.
It is further suggested that the combination of urine sediment
score and a positive [TIMP-2]•[IGFBP-7] result could potentially
have higher sensitivity and speciﬁcity compared with the indi-
vidual biomarker results, as was previously shown, as well as
with urine NGAL, KIM-1 and IL-18 levels [53–55].
Finally, Vijayan et al. [41] correctly stated that the cost beneﬁt
of [TIMP-2]•[IGFBP-7] testing is unknown. If early recognition
and treatment leads to reduced severity of AKI, a favourable
cost–beneﬁt ratio of [TIMP-2]•[IGFBP-7] might be anticipated,
but currently there are no data to support the premise that
early recognition of kidney injury with [TIMP-2]•[IGFBP-7] or
other AKI biomarkerswill prevent the progression of AKI or be as-
sociated with a cost beneﬁt to the patient or institution. The rela-
tively low speciﬁcity of the biomarker tests leading to false-
positive results may lead to unnecessary and expensive diagnos-
tic and therapeutic evaluations.
Conclusions
The combination of two cell cycle arrest markers (TIMP-2 and
IGFBP-7) for the early detection of AKI is promising, but its clinical
impact is still unproven.We agreewith Prowle et al. [56] that ﬁnd-
ing a statistical association of any biomarker with the develop-
ment of AKI is relatively easy, but demonstrating that such a
biomarker meaningfully alters practice, let alone clinical out-
comes, is much trickier [57]. AKI complicating critical illness is
highly heterogeneous in severity, aetiology and timing [58], all
of which may variably affect biomarker results. Thus, deﬁning
the appropriate timing and frequency of biomarker measure-
ment and interpreting these results in individual patients are ex-
tremely difﬁcult.
We also agree with the conclusions and recommendations of
the American Society of Nephrology AKI Advisory Group that ap-
proval of the novel biomarker combination of [TIMP-2]•[IGFBP-7]
is a positive step in the search for robust and accurate means of
early diagnosis of AKI. However, clinicians should understand
the utility and limitations of this test before deciding whether
to make it available at their institution [41].
To translate this advancement in AKI biomarkers tomeaning-
ful improvement in clinical outcomes, standardization of care
and early nephrology involvement will be important. We believe
that for now careful clinical appraisal using close clinical haemo-
dynamic monitoring of the patient, avoiding nephrotoxic expo-
sures and regular follow-up of standard parameters such as SCr
anddiuresis remain the cornerstones in the approach to a patient
at risk of AKI. Additional trials to study the role of cell cycle and
other biomarkers in preventive strategies and interventional
trials are needed to assess its effectiveness in improving out-
comes in AKI.
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